Charles S. Cox, Jr., M.D. is Professor and Clare A. Glassell Distinguished Chair of Pediatric Surgery, and the George and Cynthia Mitchell Distinguished Chair in Neuroscience, directing the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine at the University of Texas McGovern Medical School at Houston. He co-directs the Texas Trauma Institute and directs the Pediatric Trauma Program at the Children’s Memorial Hermann Hospital in the Texas Medical Center.
A Texas native, Dr. Cox received his undergraduate degree from the University of Texas at Austin in the Plan II Liberal Arts Honors Program. Upon graduating from the University of Texas Medical Branch, he completed his Surgery residency at the University of Texas McGovern Medical School at Houston. Further post-graduate fellowships were completed in Pediatric Surgery at the University of Michigan, an NIH T32 sponsored clinical and research fellowship at the Shriner’s Burns Institute, and Surgical Critical Care/Trauma at the University of Texas Medical School at Houston. He is certified by the American Board of Surgery in Surgery, with added qualifications in Pediatric Surgery and Surgical Critical Care. He served in Afghanistan with the 82nd Airborne in the 909th Forward Surgical Team in 2002.
The Pediatric Translational Laboratories and Pediatric Program in Regenerative Medicine represent a multi-disciplinary effort that addresses problems that originate with traumatic injury and the consequences of resuscitation and critical care. The Program focuses on cell based therapy for traumatic brain injury, and related neurological injuries, completing numerous clinical trials in this area. The program has been continuously funded since 1998 through the National Institutes of Health, Department of Defense, Texas Emerging Technology Funds, Industry Collaboration (Athersys, Inc.; Celgene Cellular Therapeutics; CBR, Inc; HopeBio, Inc.), and philanthropic contributions. The Program is housed in state-of-the-art laboratory facilities, and includes three cGMP, Class 10,000 facilities for the production of clinical grade cell and tissue products: Hoffberger Cellular Therapeutics Laboratory and the Griffin Stem Cell Therapeutics Research Laboratory.
He is the author of over 250 scientific publications, 20 book chapters, and is the editor of texts entitled, Progenitor Cell Therapy for Neurological Injury and Cellular Therapy for Neurological Injury.
